Sionna Therapeutics (NASDAQ:SION) Rating Increased to Strong-Buy at Lifesci Capital

Lifesci Capital upgraded shares of Sionna Therapeutics (NASDAQ:SION) to a strong-buy rating in a research report released on Wednesday,Zacks.com reports.

A number of other analysts have also weighed in on SION. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. BTIG Research restated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Citigroup assumed coverage on Sionna Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, Citizens Jmp began coverage on Sionna Therapeutics in a research report on Tuesday. They set a “market outperform” rating and a $63.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.63.

Sionna Therapeutics Trading Up 1.9%

Sionna Therapeutics stock opened at $38.03 on Wednesday. Sionna Therapeutics has a 12 month low of $7.26 and a 12 month high of $45.00. The company has a market capitalization of $1.70 billion and a price-to-earnings ratio of -7.81. The business’s fifty day simple moving average is $40.02 and its two-hundred day simple moving average is $34.79.

Insiders Place Their Bets

In other news, Director Peter A. Thompson sold 33,356 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the sale, the director owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the transaction, the director directly owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 382,368 shares of company stock valued at $15,898,607. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Braidwell LP purchased a new position in Sionna Therapeutics during the second quarter valued at $18,770,000. Eventide Asset Management LLC bought a new position in shares of Sionna Therapeutics during the 4th quarter valued at approximately $26,290,000. Vanguard Group Inc. increased its holdings in Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after acquiring an additional 512,803 shares in the last quarter. State Street Corp increased its holdings in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after acquiring an additional 453,196 shares in the last quarter. Finally, Viking Global Investors LP raised its stake in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after acquiring an additional 242,427 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.